Skip to main content

Alkermes plc.

corporate_fare Company Profile

Alkermes plc.

ALKS·NASDAQ·Life Sciences·CIK 0001520262

Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in neuroscience. The company has a portfolio of proprietary commercial products for treating alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and narcolepsy. It also maintains a pipeline of clinical and preclinical candidates for neurological disorders. Alkermes is headquartered in Ireland, with a corporate office and R&D center in Massachusetts, and a manufacturing facility in Ohio. On February 12, 2026, Alkermes completed the acquisition of Avadel Pharmaceuticals plc, adding LUMRYZ to its proprietary commercial products and gaining a commercial organization experienced in narcolepsy. The acquisition involved consideration of $21.00 per Avadel ordinary share in cash at closing, plus a non-transferable contingent value right for a potential additional cash payment of $1.50 per Avadel share upon achieving a specified milestone. Alkermes' proprietary commercial products include treatments for schizophrenia, narcolepsy, bipolar I disorder, alcohol dependence, and opioid dependence in the U.S. Additionally, the company licenses its proprietary technologies for key third-party products. For example, RISPERDAL CONSTA, indicated for schizophrenia and bipolar I disorder, is commercialized by Janssen Pharmaceuticals, Inc. in a licensed territory.

Alkermes plc. (NASDAQ:ALKS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for ALKS at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Alkermes Reports FY2025 Revenue & Profit Decline, Projects FY2026 Net Loss Amid Strategic Investments
  • Alkermes Reports Q4/FY 2025 Results, Projects FY 2026 GAAP Net Loss Amidst Strategic Investments
  • Alkermes Completes Avadel Acquisition, Secures $1.525B Term Loans to Fund Strategic Expansion into Sleep Medicine
  • Alkermes Highlights Strong 2025 Revenue, Alixorexton Breakthrough Therapy, and Strategic Avadel Acquisition
  • Alkermes' Alixorexton Receives FDA Breakthrough Therapy Designation for Narcolepsy Type 1

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.48B
Net Income
$241.66M
Diluted EPS
$1.43
Op. Cash Flow
$520.75M
Free Cash Flow
$480.33M
Gross Profit
$1.28B
Operating Income
$253.96M
Cash & Equivalents
$388.57M
Debt / Equity
0.00×
Net Margin
16.4%
Shares Outstanding
165.61M sh
Source: 10-K · filed 2026-02-25 · accession 0001193125-26-068925
$45.5 +1.25% today
52-week range · as of 2026-11-12 $27 – $55.67
Market cap
$7.55B
Volume
1.1M (0.6× avg)
3-mo avg 1.7M
Live data · 2026-11-22 12:44 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ALKS - Filings & News (Page 2)

ALKS
Feb 25, 2026, 9:31 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $32.41
Real-time Price: $45.50 info
Change: +$13.09 (+40%) info
Market Cap: $7.552B info
ALKS
Feb 25, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $33.60
Real-time Price: $45.50 info
Change: +$11.90 (+35%) info
Market Cap: $7.552B info
ALKS
Feb 12, 2026, 7:37 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $34.92
Real-time Price: $45.50 info
Change: +$10.58 (+30%) info
Market Cap: $7.552B info
ALKS
Jan 12, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $29.60
Real-time Price: $45.50 info
Change: +$15.90 (+54%) info
Market Cap: $7.552B info
ALKS
Jan 06, 2026, 7:07 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $28.82
Real-time Price: $45.50 info
Change: +$16.68 (+58%) info
Market Cap: $7.552B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets